Dyax Corp. (DYAX) said that it has received the FDA approval for Kalbitor to treat acute attacks of hereditary angioedema or HAE in patients 16 years of age and older.
HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling, which can occur in the abdomen, face, hands, feet and airway.
Kalbitor, which is discovered and developed by Dyax, is the first subcutaneous HAE treatment approved in the U.S.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.